ArticleInternational journal of molecular sciences2025
Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression.
Abstract readMulticenter Study
In one paragraph
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.Cancer biology & therapy · 2026Review
- Single-Cell Analysis Reveals Pre-Existing Basal-Associated Epithelial States in Metastatic Hormone-Naïve Prostate Cancer.International journal of molecular sciences · 2026Article
- Biomarkers and testing in pathology.Current opinion in urology · 2026Review
- Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review).International journal of oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Marta Garcia de HerrerosTranslational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.
Natalia JiménezTranslational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.ORCID 0000-0002-7057-0426
Joan PadrosaTranslational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.ORCID 0000-0002-3354-5811
Caterina AversaTranslational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.
Laura Ferrer-MileoTranslational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.ORCID 0000-0002-2933-3357
Samuel García-EsteveTranslational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.ORCID 0000-0002-7680-2048
Leonardo Rodríguez-CarunchioUro-Oncology Unit, Hospital Clínic, University of Barcelona, 08036 Barcelona, Spain.
Isabel TriasUro-Oncology Unit, Hospital Clínic, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-9841-4380
Laia Fernández-MañasTranslational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.ORCID 0009-0002-2580-1763
Mercedes Marín-AguileraTranslational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.
Mariana AltamiranoMedical Oncology Department, Hospital Clínic, 08036 Barcelona, Spain.
Manuel MazariegosTranslational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.
Albert FontMedical Oncology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, 08916 Badalona, Spain.
Alejo Rodriguez-VidaMedical Oncology Department, Hospital del Mar, 08003 Barcelona, Spain.
Miguel Ángel ClimentMedical Oncology Service, Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain.
Sara CrosMedical Oncology Department, Hospital General de Granollers, 08402 Barcelona, Spain.
Isabel ChirivellaDepartment of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0002-0733-3276
Mariona FigolsMedical Oncology Department, Fundació Althaia, Xarxa Assistencial Universitària de Manresa, 08242 Manresa, Spain.ORCID 0000-0001-7563-3812
Núria Sala-GonzálezDepartment of Medical Oncology, Institut Català d'Oncologia, 17007 Girona, Spain.
Vicenç Ruiz de PorrasBadalona Applied Research Group in Oncology (B-ARGO), Institut Català d'Oncologia, 08916 Germans Trias i Pujol Badalona, Spain.ORCID 0000-0002-4352-1784
Juan Carlos PardoMedical Oncology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, 08916 Badalona, Spain.
Aleix PratTranslational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.ORCID 0000-0003-2377-540X
Òscar ReigTranslational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.
Begoña MelladoTranslational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.ORCID 0000-0002-8088-5966
Funding
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M''Ayudas SEOM de Intensificación para Investigadores Jóvenes'' naCERCA Programme/Generalitat de Catalunya naContracte Clínic Recerca "Emili Letang i Josep Font" 2023 naEuropean Union PI18/00714 and PI24/00631Instituto de Salud Carlos III PI18/00714 and PI24/00631Janssen-Pharmaceuticals 212082PCR4056NCI NIH HHS U10 CA180820
Abstract
Alterations in the
Indexed as
Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantPTEN PhosphohydrolaseTranscriptomeAgedAged, 80 and overBiomarkers, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm MetastasisPrognosisBiomarkers, TumorPTEN PhosphohydrolasePTEN protein, humanandrogen deprivation therapyandrogen receptor signaling inhibitorsbiomarkersCHAARTED trialdocetaxelhormone-sensitive prostate cancerPTEN
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.